Videos

In this fourth installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss the key side effects seen in clinical trials of first-line treatments for patients with pancreatic cancer. View Video ›

Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.

View Video ›

In this third installment, Michael Pishvaian, MD, PhD, and Tanios Bekaii-Saab, MD, discuss why median progression-free survival is so important when considering the various transformational trials in pancreatic cancer. View Video ›

In this second installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss various first-line treatments for metastatic pancreatic ductal adenocarcinoma from the MPACT, PRODIGE-4, and NAPOLI 3 trials. View Video ›

In this first installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss how patients are evaluated for pancreatic cancer. View Video ›

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses updated data from the phase 1a/1b trial of zongertinib in patients with HER2 aberration-positive solid tumors. In this video, she reports data from phase 1b, the ongoing dose expansion phase, which includes patients with HER2 mutation–positive NSCLC and focuses on nursing considerations for managing adverse events. View Video ›

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation. View Video ›

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations. View Video ›

Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications. View Video ›

Experts provide notable points on ovarian function suppression therapy, including suitable patient populations, effective utilization, and valuable navigation approaches. View Video ›